Sort   by:  
 Page size 
TranscriptomicsExpression data from a reversible dasatinib-resistant state in long-term dasatinib-treated c-KIT-mutated Kasumi-1 cell line
Long-term treatment of Kasumi-1 cells at clinically attained doses of dasatinib led to decreased drug-sensitivity by means of IC50 values (relative to treatment-naive cells). Changes were paralled by profound alterations in c-KIT expression and cell signaling signatures. Upon brief discontinuation o...
ORGANISM(S): Homo sapiens 
2013-11-27 | E-GEOD-39073 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human cancer-associated fibroblasts treated with dasatinib
Effect of Dasatinib on primary cancer-associated fibroblasts from lung cancer specimens.
ORGANISM(S): Homo sapiens 
2011-01-12 | E-MEXP-2546 | biostudies-arrayexpress
TranscriptomicsGene expression signatures of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib
Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasa...
ORGANISM(S): Homo sapiens 
2013-07-31 | E-GEOD-33290 | biostudies-arrayexpress
TranscriptomicsNoncoding RNA expression profile of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib
Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasa...
ORGANISM(S): Homo sapiens 
2013-07-31 | E-GEOD-33288 | biostudies-arrayexpress
TranscriptomicsProtein coding gene expression profile of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib
Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasa...
ORGANISM(S): Homo sapiens 
2013-07-31 | E-GEOD-33224 | biostudies-arrayexpress
TranscriptomicsGene expression profiles of dasatinib-resistant and dasatinib-sensitive pancreatic cancer cell lines
Gene profiles from three dasatinib-resistant and three dasatinib-sensitive pancreatic cancer cell lines were compared by microarray analysis. RNA from three dasatinib-resistant (MiaPaCa2, Panc1, SU8686) and three dasatinib-sensitive (Panc0504, Panc0403, Panc1005) pancreatic cancer cell lines were ex...
ORGANISM(S): Homo sapiens 
2015-02-24 | E-GEOD-59357 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of human K562 cells treated with dasatinib
Total RNA from 1e7 K562 cells either mock-treated with DMSO or treated with 100nM dasatinib in two biological repeats for 3 hours
ORGANISM(S): Homo sapiens 
2009-04-02 | E-MEXP-1561 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human EndoC-betaH1 cells treated with imatinib or dasatinib
EndoC-betaH1 cells were cultured at standard conditions for 6h with or without 10 microM imatinib or 125 nM dasatinib. Cells were then used for total RNA isolation, and the RNA was sequenced by eurofinsgenomics.eu. Three replicates from each group was analyzed. Both imatinib and dasatinib are BCR-Ab...
ORGANISM(S): Homo sapiens 
2026-09-21 | E-MTAB-17592 | biostudies-arrayexpress
TranscriptomicsComparative genomic hybridization to structurally characterize a new-generated dasatinib and imatinib mouse BCR-ABL resistant cell line
Characterization of structural genomic alteration in new-generated dasatinib and imatinib mouse BCR-ABL resistant cell line
ORGANISM(S): Mus musculus 
2007-08-01 | E-MEXP-997 | biostudies-arrayexpress
ProteomicsIntegration of Proteomics, Phosphoproteomics and Loss-of-function Screen Identifies WEE1 Inhibition as a Combination Therapy with Dasatinib against Proneural Glioblastoma.
Background: Glioblastoma (GB) is the most common primary malignancy of the central nervous system. It can be classified into proneural (PN), mesenchymal (MES) and classical (CL) based on transcriptomics. Due to increased resistance against targeted therapies, such as the PN subtype and dasatinib, id...
ORGANISM(S): Homo sapiens (Human) 
2026-01-12 | PXD039264 | Pride
Wee1 Dasatinib Glioblastoma Silac 
Sort   by:  
 Page size